| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Antigenic and virological characteristics of SARS-CoV-2 variants BA.3.2, XFG, and NB.1.8.1
|
Guo, Caiwan
|
|
|
25 |
7 |
p. e374-e377
|
artikel
|
| 2 |
Antimicrobials in serious illness and end-of-life care: lifting the veil of silence
|
Rosa, William E
|
|
|
25 |
7 |
p. e416-e431
|
artikel
|
| 3 |
Beyond mosquitoes and malaria—ivermectin in Africa
|
Hammann, Felix
|
|
|
25 |
7 |
p. 703-705
|
artikel
|
| 4 |
Breakthrough atypical mpox in a vaccinated individual with high antibody titres
|
Byrne, Joanne
|
|
|
25 |
7 |
p. e439
|
artikel
|
| 5 |
Cash incentives as a bold new strategy for tuberculosis control
|
Ndjeka, Norbert
|
|
|
25 |
7 |
p. 707-708
|
artikel
|
| 6 |
Continuous on-site mentoring for infection prevention and control and antimicrobial stewardship programmes in war-affected settings: the example of Ukraine
|
Vodianyk, Arkadii
|
|
|
25 |
7 |
p. 714-716
|
artikel
|
| 7 |
Correction to Lancet Infect Dis 2024; 24: e604–05
|
|
|
|
25 |
7 |
p. e383
|
artikel
|
| 8 |
Correction to Lancet Infect Dis; published online May 19. https://doi.org/10.1016/S1473-3099(25)00341-X
|
|
|
|
25 |
7 |
p. e383
|
artikel
|
| 9 |
Correction to Lancet Infection 2025; published online April 16. https://doi.org/10.1016/S1473-3099(25)00088-X
|
|
|
|
25 |
7 |
p. e383
|
artikel
|
| 10 |
Effectiveness of sulfadoxine–pyrimethamine plus amodiaquine and dihydroartemisinin–piperaquine for seasonal malaria chemoprevention in Uganda: a three-arm, open-label, non-inferiority and superiority, cluster-randomised, controlled trial
|
Nuwa, Anthony
|
|
|
25 |
7 |
p. 726-736
|
artikel
|
| 11 |
Effects of conditional cash transfers and pre-test and post-test tuberculosis counselling on patient outcomes and loss to follow-up across the continuum of care in South Africa: a randomised controlled trial
|
Ismail, Nazir
|
|
|
25 |
7 |
p. 764-774
|
artikel
|
| 12 |
Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial
|
Haidar, Ghady
|
|
|
25 |
7 |
p. 813-826
|
artikel
|
| 13 |
Ending sleeping sickness in Guinea
|
Balakrishnan, Vijay Shankar
|
|
|
25 |
7 |
p. 722
|
artikel
|
| 14 |
Esperança Sevene—Mozambique's expert on drug safety
|
Kirby, Tony
|
|
|
25 |
7 |
p. 719
|
artikel
|
| 15 |
Evaluating H56:IC31 vaccine in tuberculosis recurrence prevention
|
Gong, Wenping
|
|
|
25 |
7 |
p. 705-707
|
artikel
|
| 16 |
Expanding seasonal malaria chemoprevention beyond the Sahel region
|
ter Kuile, Feiko O
|
|
|
25 |
7 |
p. 702-703
|
artikel
|
| 17 |
GLASS report on antibiotic use data for 2022
|
Jesudason, Timothy
|
|
|
25 |
7 |
p. e384
|
artikel
|
| 18 |
Humanitarian catastrophe in Sudan
|
Burki, Talha
|
|
|
25 |
7 |
p. e387-e388
|
artikel
|
| 19 |
Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis disease recurrence in HIV-negative adults successfully treated for drug-susceptible pulmonary tuberculosis: a double-blind, randomised, placebo-controlled, phase 2b trial
|
Borges, Álvaro H
|
|
|
25 |
7 |
p. 751-763
|
artikel
|
| 20 |
Infectious disease surveillance update
|
McQuillan, Cahal
|
|
|
25 |
7 |
p. e388
|
artikel
|
| 21 |
Joseph Kamgno—a labour of love
|
Kazi, Farooq
|
|
|
25 |
7 |
p. 721
|
artikel
|
| 22 |
Julian Edmund Davies
|
Bagcchi, Sanjeet
|
|
|
25 |
7 |
p. 718
|
artikel
|
| 23 |
Louise Kelly-Hope—infectious diseases and climate change
|
Samarasekera, Udani
|
|
|
25 |
7 |
p. 720
|
artikel
|
| 24 |
Making the invisible visible
|
Haslam, Elizabeth
|
|
|
25 |
7 |
p. 725
|
artikel
|
| 25 |
Marginalised communities and COVID-19
|
Das, Manjulika
|
|
|
25 |
7 |
p. 724
|
artikel
|
| 26 |
Measles and rubella eradication: commitment to a global target is now a matter of urgency
|
Durrheim, David N
|
|
|
25 |
7 |
p. 716-717
|
artikel
|
| 27 |
Mpox Continental Response Plan 2.0
|
Nakkazi, Esther
|
|
|
25 |
7 |
p. e385
|
artikel
|
| 28 |
Mpox vaccination: a dose of protection, but is it enough?
|
Raccagni, Angelo Roberto
|
|
|
25 |
7 |
p. 709-710
|
artikel
|
| 29 |
Mycoplasma pneumoniae infection in adult inpatients during the 2023–24 outbreak in France (MYCADO): a national, retrospective, observational study
|
Gavaud, Ariane
|
|
|
25 |
7 |
p. 801-812
|
artikel
|
| 30 |
Mycoplasma pneumoniae infections: changing the clinical approach to an evolving disease
|
Bongiovanni, Marco
|
|
|
25 |
7 |
p. 711-713
|
artikel
|
| 31 |
Navigating treatment duration in osteoarticular Candida infections
|
Dinh, Aurélien
|
|
|
25 |
7 |
p. e370-e371
|
artikel
|
| 32 |
Navigating treatment duration in osteoarticular Candida infections – Authors' reply
|
Sprute, Rosanne
|
|
|
25 |
7 |
p. e372-e373
|
artikel
|
| 33 |
Need for inclusion of high-risk populations and standardisation of immunogenicity outcomes in adult pneumococcal vaccine trials
|
Harboe, Zitta Barrella
|
|
|
25 |
7 |
p. e378-e379
|
artikel
|
| 34 |
Oral treatment of Whipple's disease with doxycycline and hydroxychloroquine versus intravenous therapy with ceftriaxone followed by oral trimethoprim–sulfamethoxazole in Germany: a phase 2/3, prospective, open-label, randomised, controlled, non-inferiority trial
|
Moos, Verena
|
|
|
25 |
7 |
p. 788-800
|
artikel
|
| 35 |
Remembering deaf people's experiences of lockdown
|
Ranscombe, Peter
|
|
|
25 |
7 |
p. 723
|
artikel
|
| 36 |
Research in brief
|
Venkatesan, Priya
|
|
|
25 |
7 |
p. e389
|
artikel
|
| 37 |
Safety and effectiveness of MVA-BN vaccination against mpox in at-risk individuals in Germany (SEMVAc and TEMVAc): a combined prospective and retrospective cohort study
|
Hillus, David
|
|
|
25 |
7 |
p. 775-787
|
artikel
|
| 38 |
Safety and efficacy of repeat ivermectin mass drug administrations for malaria control (RIMDAMAL II): a phase 3, double-blind, placebo-controlled, cluster-randomised, parallel-group trial
|
Somé, A Fabrice
|
|
|
25 |
7 |
p. 737-750
|
artikel
|
| 39 |
Sipavibart: when a success changes into a failure
|
Focosi, Daniele
|
|
|
25 |
7 |
p. 713-714
|
artikel
|
| 40 |
Somalia reinforces routine immunisation
|
Das, Manjulika
|
|
|
25 |
7 |
p. e386
|
artikel
|
| 41 |
Time to prioritise invasive fungal diseases
|
The Lancet Infectious Diseases,
|
|
|
25 |
7 |
p. 701
|
artikel
|
| 42 |
Tuberculosis crisis in Ecuadorian prisons: an outbreak of fake news
|
Garcia-Bereguiain, Miguel Angel
|
|
|
25 |
7 |
p. e380
|
artikel
|
| 43 |
Tuberculosis preventive therapy: scientific and ethical considerations for trials of ultra-short regimens
|
Walker, Timothy M
|
|
|
25 |
7 |
p. e432-e438
|
artikel
|
| 44 |
Unravelling the pathogenesis of Oropouche virus
|
Có, Anna Clara Gregório
|
|
|
25 |
7 |
p. e381-e382
|
artikel
|
| 45 |
Whipple's disease: from in-vitro data to bedside practice via trial results
|
Puéchal, Xavier
|
|
|
25 |
7 |
p. 710-711
|
artikel
|
| 46 |
Zika virus: advancing a priority research agenda for preparedness and response
|
Lackritz, Eve M
|
|
|
25 |
7 |
p. e390-e401
|
artikel
|
| 47 |
Zika virus vaccines and monoclonal antibodies: a priority agenda for research and development
|
Ostrowsky, Julia T
|
|
|
25 |
7 |
p. e402-e415
|
artikel
|
Tijdschrift beschrijving